ERBB2 and neoplasm: Pyrotinib in combination with capecitabine has been approved in China for the treatment of HER2+ mBC previously treated with trastuzumab and taxane [82], and a PANDORA phase 2 trial demonstrated that pyrotinib plus docetaxel had an acceptable safety profile and promising anti-tumor effect as a first-line treatment option for patients with HER2+ mBC [83].